Introduction
- The osteoporosis and HRT market was valued at $8.3 billion in 2003 and is
forecast to grow to $17.9 billion by 2014, driven by a number of novel
osteoporosis drug launches before 2009. Since the Womens Health Initiative,
the HRT market has been in decline and non-hormonal osteoporosis drugs have
partially realized the opportunity to increase market share and value,
further boosting sector growth.
Scope of this report
- Epidemiology of female and male osteoporosis in the seven major markets
- Country specific forecasts based on IMS MIDAS data of key ATC classes
A11C2; G3C; G3E; G3F; H4A; H4V; M5B1; M5B2; M5B9
- Analysis of WHI impact on the osteoporosis and HRT market and portfolio
management strategy in hormone therapy
- Extensive secondary research and utilization of licensed and in-house
databases augmented by primary research interviews with key opinion leaders
Research and analysis highlights
- The osteoporosis market is forecast to be worth $14.7 billion by 2014.
Growth is driven by uplift after the WHI and new product launches to 2009.
The market will face its first major genericization when Fosamax loses
patent protection. Generics are expected in the UK in 2005, followed by
patent expiries in Europe in 2007 and the US in 2008.
- The WHI wiped $850 million off HRT market value in 2003, sending the
sector into decline. Wyeth and other players in the market have responded
with investment in R&D to expand their portfolios to meet the demand for
tailored treatment in the menopausal population.
- Additional indications are critical in maximizing osteoporosis drugs
commercial potential. Lillys Evista and Pfizers lasofoxifene are in trials
for breast cancer and cardiovascular disease prevention, and Novartiss
bisphosphonate Zometa is moving into the osteoporosis market. Such
indications could add over $1 billion to brand revenues.
Key reasons to read this report
- Predict the impact of key growth drivers on the market, such as
intermittent dosing and multiple indications
- Review leading drug class and identify key success factors within this
sector
- Quantify the impact of key patent expiries using the forecasting model
View Cart
